Proteomic and Physiological Markers of Exercise-induced Physiological Stress and Fatigue in Grand Tour Cycling

NCT06165588 | Completed DMC

• 1 other identifier: S63402
• Study Type: observational
• Target: 7
• Locations: 1 country
• Sites: 1

Brief Summary

This project aims to identify the effect of a 3-week grand tour (e.g. Tour de France) on physiological markers and the blood proteome in world-class cyclists.

Conditions

Exercise Fatigue

Keywords

Cycling; Proteomics; Grand tour

Outcome Measures

Primary Outcomes (3)

• Serum proteome abundance of cyclists during Tour de France

  Change in serum proteome between start and end of Tour de France

  Start of the Tour de France (day 0) - last day of the Tour de France (day 23)

• Serum GDF15 (Growth and differentiation factor 15) concentration

  Serum GDF15 throughout the grand tour

  Start of the Tour de France (day 0) - restday 1 (day 11) - restday 2 (day 17) - last day of the Tour de France (day 23)

• Blood haemoglobin concentration

  Haematological profile of cyclists

  Start of the Tour de France (day 0) - restday 1 (day 11) - restday 2 (day 17) - last day of the Tour de France (day 23)

Secondary Outcomes (6)

• Serum Leptin concentration

  Start of the Tour de France (day 0) - restday 1 (day 11) - restday 2 (day 17) - last day of the Tour de France (day 23)

• Red blood cell concentration

  Start of the Tour de France (day 0) - restday 1 (day 11) - restday 2 (day 17) - last day of the Tour de France (day 23)

• White blood cell concentration

  Start of the Tour de France (day 0) - restday 1 (day 11) - restday 2 (day 17) - last day of the Tour de France (day 23)

• Serum ghrelin concentration

  Start of the Tour de France (day 0) - restday 1 (day 11) - restday 2 (day 17) - last day of the Tour de France (day 23)

• Serum FGF21 (fibroblast growth factor 21) concentration

  Start of the Tour de France (day 0) - restday 1 (day 11) - restday 2 (day 17) - last day of the Tour de France (day 23)

Study Arms (1)

Cyclists

Elite cyclists participating in the Tour de France

Other: Tour de France

Interventions

Tour de France OTHER

Participating in the Tour de France as cyclist

Cyclists

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects participating in Tour de France

You may qualify if:

• Cyclist participating in the Tour de France

You may not qualify if:

• Younger than 18years old

Sponsors & Collaborators

• KU Leuven: lead

Study Sites (1)

KU Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 31, 2023
• First Posted: December 11, 2023
• Study Start: July 6, 2019
• Primary Completion: July 28, 2019
• Study Completion: August 31, 2023
• Last Updated: December 11, 2023

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)